MWNA
STML

Marshall Wace North America’s Stemline Therapeutics, Inc. STML Stock Holding History

Marshall Wace North America’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,223
Closed -$96K – 1749
2019
Q3 		$96K Buy
+9,223
New +$121K ﹤0.01% 1066
2019
Q1 		– Sell
-3,324
Closed -$32K – 2061
2018
Q4 		$32K Buy
+3,324
New +$43.1K ﹤0.01% 1352

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace North America's STML Position: Q4 2019 in Review

Marshall Wace North America sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 9,223 shares — an estimated $96K sold.

Marshall Wace North America first reported a position in STML in Q4 2018 and held it in 2 quarters. The position peaked at $96K in Q3 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Marshall Wace North America reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 9,223 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $96K.
  • Marshall Wace North America first reported a position in Stemline Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Marshall Wace North America's Stemline Therapeutics, Inc. position peaked at $96K in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.